Cross-reacting antiporcine factor VIII inhibitors in patients with acquired hemophilia A

Maddie Stephen; Carolyne Elbaz; Hina Hanif; Katerina Pavenski; Jerry Teitel; Michelle Sholzberg

doi:10.1016/j.rpth.2024.102553

Cross-reacting antiporcine factor VIII inhibitors in patients with acquired hemophilia A

Res Pract Thromb Haemost. 2024 Aug 22;8(6):102553. doi: 10.1016/j.rpth.2024.102553. eCollection 2024 Aug.

Authors

Maddie Stephen¹, Carolyne Elbaz², Hina Hanif³, Katerina Pavenski^{2

3}, Jerry Teitel², Michelle Sholzberg^{2

3}

Affiliations

¹ Department of Medicine, Division of Hematology, University of Toronto, Toronto, Ontario, Canada.
² Department of Medicine, Division of Hematology/Oncology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
³ Department of Laboratory Medicine and Pathobiology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.

Abstract

•Recombinant porcine factor VIII (rpFVIII) is a hemostatic treatment for bleeding in acquired hemophilia A.•The efficacy of rpFVIII can be negatively affected by cross-reacting anti-human FVIII antibodies.•In this cohort, 52% of patients with acquired hemophilia A had baseline cross-reacting antibodies.•Cross-reacting antibodies were associated with decreased FVIII activity levels post-rpFVIII infusion.

Keywords: Obizur; acquired hemophilia A; inhibitors; rpFVIII.